(Q28247445)

English

A randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density

scientific article (publication date: February 2015)

In more languages

Statements

scholarly article

0 references

1 reference

based on heuristic

inferred from title

A randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density (English)

0 references

phase II clinical trial

0 references

1 reference

based on heuristic

inferred from title

author name string

Robert R Recker

1

0 references

Charles T Benson

2

0 references

Toshio Matsumoto

3

0 references

Michael A Bolognese

4

0 references

Deborah A Robins

5

0 references

Jahangir Alam

6

0 references

Alan Y Chiang

7

0 references

Leijun Hu

8

0 references

John H Krege

9

0 references

Bruce H Mitlak

11

0 references

Stephen L Myers

12

0 references

Hideaki Sowa

10

0 references

language of work or name

0 references

publication date

February 2015

0 references

Journal of Bone and Mineral Research

0 references

30

0 references

2

0 references

216-24

0 references

A reference standard for the description of osteoporosis

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.2351

21 January 2018

Update on bone anabolics in osteoporosis treatment: rationale, current status, and perspectives

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.2351

21 January 2018

Sclerostin: therapeutic horizons based upon its actions

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.2351

21 January 2018

Osteocyte regulation of bone mineral: a little give and take.

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.2351

21 January 2018

Sclerostin: current knowledge and future perspectives

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.2351

21 January 2018

Characterization of the Structural Features and Interactions of Sclerostin: MOLECULAR INSIGHT INTO A KEY REGULATOR OF Wnt-MEDIATED BONE FORMATION

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.2351

21 January 2018

Sclerostin regulates release of bone mineral by osteocytes by induction of carbonic anhydrase 2.

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.2351

21 January 2018

Regulation of Wnt/β-catenin signaling within and from osteocytes

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.2351

21 January 2018

Bone metabolism and histomorphometric changes in murine models treated with sclerostin antibody: a systematic review

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.2351

21 January 2018

Sclerostin monoclonal antibody therapy with AMG 785: a potential treatment for osteoporosis

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.2351

21 January 2018

Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.2351

21 January 2018

Romosozumab in postmenopausal women with low bone mineral density.

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.2351

21 January 2018

Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.2351

21 January 2018

The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosis

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.2351

21 January 2018

Van Buchem disease: clinical, biochemical, and densitometric features of patients and disease carriers

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.2351

21 January 2018

Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.2351

21 January 2018

Sclerostin stimulates osteocyte support of osteoclast activity by a RANKL-dependent pathway

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.2351

21 January 2018

Involvement of WNT/β-catenin signaling in the treatment of osteoporosis.

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.2351

21 January 2018

Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.2351

21 January 2018

The natural history of sclerosteosis

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.2351

21 January 2018

Identifiers

10.1002/JBMR.2351

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q28247445&oldid=1244399231"